从实验台到床旁:血管加压素及其类似物用于失血性休克复苏的机制阐释与临床转化
失血性休克仍是平民和军事创伤中可预防死亡的主要原因。传统儿茶酚胺类升压药在活动性出血期间存在器官灌注不良等局限。血管加压素及其类似物具有非肾上腺素能药理特性,可能快速恢复血流动力学、减少输血需求并提供器官保护,但临床试验结果不一致,患者选择和最佳剂量未定,特利加压素在美国的处方集准入和肠道缺血风险等安全性问题持续存在。本文综述其药理、机制及临床前/临床证据,并介绍正在进行的多中心随机CAVALIER试验(NCT05958342),旨在为个体化复苏策略提供依据。
要点
- 失血性休克中早期使用升压药存在争议,传统儿茶酚胺类因器官灌注不良和活动性出血期间净获益不确定而受限。
- 血管加压素及其类似物(特别是特利加压素)具有非肾上腺素能药理特性,可能快速恢复血流动力学、减少输血需求并提供器官保护。
- 临床 adoption 受限于关键知识空白、试验结果不一致、患者选择和最佳剂量未解决、监管批准和成本等实际障碍,以及内脏低灌注等安全性担忧。
- 正在进行的CAVALIER试验(NCT05958342)是一项多中心随机研究,探讨早期使用血管加压素。
- 特利加压素在美国的处方集准入存在挑战,肠道缺血风险是持续关注的安全性信号。
适用人群与场景
- 平民和军事创伤导致的失血性休克患者。
研究设计与关键结果
- 本文为综述,综合了血管加压素及其类似物在失血性休克复苏中的药理特征、细胞和分子机制以及临床前/临床证据。
- 现有临床试验结果不一致,患者选择和最佳剂量尚未解决。
- 特利加压素在美国的处方集准入存在挑战,肠道缺血风险是持续的安全性担忧。
- 正在进行的CAVALIER试验(NCT05958342)是一项多中心随机研究,探讨早期使用血管加压素。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 本文未给出具体推荐;作者指出血管加压素及其类似物在失血性休克复苏中的作用仍在演变,患者选择和最佳剂量未解决,安全性担忧(如内脏低灌注)持续存在。
- 作者认为需要基于证据的个体化复苏策略以改善这一高危人群的结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Hemorrhagic shock remains a leading cause of preventable mortality in civilian and military trauma, despite advances in trauma systems and resuscitation strategies. Vasopressor therapy for early resuscitation is controversial, as conventional catecholamine agents are limited by adverse effects on organ perfusion and uncertain net benefit during active bleeding. Vasopressin and its analogues (notably terlipressin) have emerged as potential alternatives, with unique non-adrenergic pharmacology that enables rapid hemodynamic restoration, reduced transfusion requirements, and organ protection-properties supported by recent molecular and translational research. However, clinical adoption is hindered by critical knowledge gaps, inconsistent trial outcomes, unresolved questions around patient selection and optimal dosing, practical barriers including regulatory approval and cost, and persistent safety concerns such as potential splanchnic hypoperfusion. This review comprehensively synthesizes the pharmacological profiles, cellular and molecular mechanisms, and preclinical/clinical evidence for vasopressin and its analogues in hemorrhagic shock resuscitation. It critically addresses current controversies, methodological limitations of existing research, and key uncertainties in clinical application-including the risks of intestinal ischemia and the challenges of formulary access for terlipressin in the US. We also highlight the ongoing CAVALIER trial (NCT05958342), a pivotal multicenter randomized study investigating early vasopressin use, and outline specific, actionable directions for mechanistic research and precision clinical trials to address unmet needs. By consolidating multidisciplinary evidence in an unbiased framework, this review clarifies the evolving role of vasopressin-based therapies and aims to inform evidence-based, individualized resuscitation strategies to improve outcomes in this high-risk population.
参考来源
- Jiang S, Chen B, Wang L, et al. Bridging bench to bedside: mechanistic elucidation and clinical translation of vasopressin and its analogues for hemorrhagic shock resuscitation. Shock. 2026. PMID: 41949845. doi:10.1097/SHK.0000000000002845
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。